Skip to content

Epilepsy Prevalence and Intervention Study in Zhejiang Province, China

Epilepsy Prevalence and Intervention Study in Zhejiang Province, China

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04944641
Enrollment
200
Registered
2021-06-29
Start date
2013-09-13
Completion date
2022-12-31
Last updated
2021-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

epilepsy prevalence, intervention

Brief summary

To carry out the epidemiological investigation on epilepsy in Zhejiang Province, China, and then establish early comprehensive intervention to help patients with epilepsy to improve seizure control and the quality of life.

Detailed description

To carry out the epidemiological investigation on epilepsy in Zhejiang Province, China, and then establish early comprehensive intervention(proper antiepileptic drugs and education intervention) to help patients with epilepsy to improve seizure control and the quality of life.

Interventions

BEHAVIORALeducation on epilepsy

education on epilepsy, including epilepsy diary, pamphlet,discussion between patients and phone visits and so on

DRUGroutine and proper antiepileptic drugs

routine and proper antiepileptic drugs

Sponsors

Hangzhou Center of Disease Control and Prevention
CollaboratorOTHER_GOV
The Central Hospital of Lishui City
CollaboratorOTHER
The Second Affiliated Hospital of Jiaxing University
CollaboratorOTHER
Zhejiang University
CollaboratorOTHER
Children's Hospital Affiliated to Zhejiang University School of Medicine
CollaboratorUNKNOWN
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

randomly group into two

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Newly diagnosed and untreated epilepsy; Aged 14 and above; Sign the informed consents.

Exclusion criteria

With intellectual development disorder; With serious heart and lung diseases.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline seizures frequency 112 monthschange from baseline seizures frequency at 12 months, seizure frequency is defined as the number of seizure attacks during 3 months before baseline or endpoint)
Change from baseline seizures frequency 224 monthschange from baseline seizures frequency at 24 months, seizure frequency is defined as the number of seizure attacks during 3 months before baseline or endpoint)
Occurrence of refractory epilepsy24 monthsoccurrence of refractory epilepsy at 24 months

Secondary

MeasureTime frameDescription
Quality of life (QOL scales)2 yearQuality of Life Scale, high scores mean a better outcome

Countries

China

Contacts

Primary ContactMei-ping Ding
dmp-neurology@zju.edu.cn13588058581

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026